Absci (ABSI) Change in Accured Expenses (2020 - 2025)
Absci (ABSI) posted Change in Accured Expenses of $2.5 million for Q3 2025, up 22.87% sequentially from $2.0 million in Q2 2025, and up 80.22% YoY from $1.4 million in Q3 2024.
Analysis
Absci (ABSI) Change in Accured Expenses (2020 - 2025) Analysis & Trends
Absci has reported Change in Accured Expenses for 6 years, with the latest figure at $2.5 million in Q3 2025.
- Quarterly Change in Accured Expenses rose 80.22% year-over-year to $2.5 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $1.9 million (up 233.87% YoY) and the FY2024 annual result came in at -$295000.0, up 75.68% from the prior year.
- Change in Accured Expenses improved to $2.5 million in Q3 2025 per ABSI's latest filing, from $2.0 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $3.9 million in Q3 2022 and troughed at -$4.5 million in Q1 2022.
- A 5-year average of -$77947.4 and a median of -$374000.0 in 2023 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2021 and 2022: Change in Accured Expenses slumped 1337.23% in 2021, then surged 437.49% in 2022.
- Over 5 years, Change in Accured Expenses stood at $2.1 million in 2021, then slumped by 123.28% to -$500000.0 in 2022, then increased by 25.2% to -$374000.0 in 2023, then soared by 303.21% to $760000.0 in 2024, then jumped by 230.79% to $2.5 million in 2025.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $2.5 million, $2.0 million, and -$3.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Absci | 1.39 Bn | 1.19 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 2.51 Mn |
| Jun 30, 2025 | 2.05 Mn |
| Mar 31, 2025 | -3.41 Mn |
| Dec 31, 2024 | 760,000.00 |
| Sep 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | 1.46 Mn |
| Mar 31, 2024 | -3.91 Mn |
| Dec 31, 2023 | -374,000.00 |
| Sep 30, 2023 | 2.96 Mn |
| Jun 30, 2023 | -1.38 Mn |
| Mar 31, 2023 | -2.43 Mn |
| Dec 31, 2022 | -500,000.00 |
| Sep 30, 2022 | 3.93 Mn |
| Jun 30, 2022 | -601,000.00 |
| Mar 31, 2022 | -4.53 Mn |
| Dec 31, 2021 | 2.15 Mn |
| Sep 30, 2021 | -1.16 Mn |
| Jun 30, 2021 | -848,000.00 |
| Mar 31, 2021 | 444,000.00 |
| Dec 31, 2020 | 1.01 Mn |